Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
Exousia Pro is in a unique position, as only 11% of ODAs are awarded at the preclinical stage. ORLANDO, FLORIDA...
Cancer
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to...
Targeted Genomics Launches CeliacDx Consumer-Initiated Testing Service
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Targeted Genomics LLC, developer of GlutenID, the only U.S. Food and Drug...
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the...
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for...
ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts
UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation...
BioNTech to Host Innovation Series R&D Day on November 11, 2025
MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of...
Evidence Against Evidence: CERN-IEEE FPGA vs. Crosetto 3D-Flow, a Breakthrough Invention Recognized 32 Years Ago That Could Have, and Can Still, Save Billions of Euros and Millions of Lives
Science vs. Consensus: An urgent call to CERN, IEEE, and the scientific community to engage with verifiable evidence, fulfill scientific...
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net...
Izotropic Launches “Breast Imaging News” Page on BreastCT.com
Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - October 28, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3)...
Kanazawa University Research: Scanning nanoprobe microscope reveals the hidden flexibility of cancer cells
KANAZAWA, Japan, Oct. 28, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, report in ACS...
Bot Image, Inc. Earns CE Mark Certification for ProstatID® AI Prostate MRI Software Under EU MDR
Certification opens the European market for the first FDA-cleared AI platform for prostate MRI interpretation. OMAHA, Neb., Oct. 27, 2025...
BioDlink Completes First International Shipment of Bevacizumab to Colombia
Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical...
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...